Business Description
Gyre Therapeutics is a San Diego-based drug development company focused on treating diseases that cause harmful scarring in organs such as the lungs and liver. Its lead product, ETUARY, is already approved for a serious lung condition and is being studied for additional uses, while a related compound called F351 is in late-stage trials targeting liver damage caused by chronic hepatitis B. The company also has several other drugs at various stages of testing for conditions affecting the liver and lungs. Founded in 2002, Gyre Therapeutics operates as a subsidiary of GNI USA Inc.
